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abusers were 1.5-fold as likely to have medically related absen-
teeism days, and 8.5 times as likely to have a disability claim
compared to controls (p < 0.01). Opioid abusers had higher
average annual medically related absenteeism days compared to
controls (26.4 days vs. 5.7 days, p < 0.01). Mean annual direct
health care costs for opioid abusers were over eight times higher
than controls ($15,884 vs. $1830, p < 0.01). Hospital inpatient
and doctor/outpatient costs accounted for 46% ($7239) and
31% ($5000) of opioid abusers’ health care costs, versus 17%
($310) and 50% ($906), respectively, for controls. Mean annual
indirect workloss costs for opioid abusers were over eight times
higher than controls ($4167 vs. $502, p < 0.01). CONCLU-
SIONS: These high costs were driven partly by high utilization
rates of medical services and prescription drugs, and higher
prevalence of workloss. Our estimates may be conservative as
only patients diagnosed with abuse were included. To the extent
that the abuse is prescription opioid abuse, payers should ensure
appropriate access to opioids while considering abuse liability of
drugs on formulary.
(For abstract PMH2 see page 256) MH2
EMERGENCY DEPARTMENT USE FOR ACUTE ALCOHOL
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OBJECTIVES: To examine use, timing and cost of Emergency
Department (ED) visits by those of college age (17–22 years) for
acute alcohol intoxication. METHODS: Cases were identiﬁed
from Massachusetts 2002 ED and hospital databases using ICD-
9 principal diagnosis codes 305.00–305.09. Hospital cases were
limited to those admitted via ED. Cost estimates include facility,
accommodations and ancillary services, reported in 2002 USD.
Charges were adjusted using a 0.55 cost-to-charge ratio.
RESULTS: Of 1803 cases identiﬁed, 52% were male and 55%
were less than 20-years old. Ambulances were used to transport
54%; law enforcement was involved in 1.5% of cases. The
majority (69%) arrived between 10:00 PM and 4:00 AM, and
70% of all visits occurred Friday through Sunday. Signiﬁcantly
(p = 0.004) more visits occurred in September and October than
any other month. The majority (94%) were treated and released
from ED, 1% was hospitalized, 2% eloped or left AMA, 2%
were transferred and 1% was recorded as unknown. Mean dura-
tion of ED visit was 5.4 hours (median: 4). Mean cost per ED
visit was $482 (median: $382) for those treated and released,
and $537 (median: $460) for those hospitalized. On average,
those admitted (n = 20) spent 2.5 days (median: 1) in the hos-
pital at a cost of $4540 (median: $2154). The cumulative hours
of ED time used in one year for treating alcohol intoxication in
this age group was 8254. Cumulative cost of ED and inpatient
care for the year was roughly $938,000. Managed care organi-
zations and commercial insurers were the responsible payers for
most cases (60%). Self-pay was noted for 24%. CONCLU-
SIONS: Acute alcohol intoxication among those of college age
results in a substantial direct medical cost, as well as an oppor-
tunity cost for ED resources during the year, particularly at the
start of the school year.
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OBJECTIVES: To determine quality-adjusted life-year (QALY)
gains associated with buprenorphine treatment for opiate addic-
tion, and estimate the potential cost savings of this treatment
from the societal perspective. METHODS: In a randomized 
clinical trial of buprenorphine therapy, subjects completed the
short-form-36 (SF-36) at baseline and every four weeks through
week-16, creating up to ﬁve data collection points for each
patient. We converted SF-36 data to SF-6D to calculate QALYs
for each patient-month through published techniques based
upon standard gamble methods. Dependent t-tests were used to
identify signiﬁcant differences in QALYs at baseline versus
QALYs at the end of each month. Our base case used a buprenor-
phine 12mg/day dosage plus annual buprenorphine treatment
clinic costs ($2356/person). We incorporated social costs of
untreated opiate addiction from the literature ($42,957/person-
year) and performed a sensitivity analysis using 8mg and 16mg
buprenorphine dosages. RESULTS: Due to dropouts, our sample
size was 100, 80, 69, 59, and 44 patients at baseline and months
one-four, respectively. QALY values (mean ± SD) for each month
were: 0.734 ± 0.091 at baseline, 0.761 ± 0.068 at month-one,
0.751 ± 0.087 at month-two, 0.754 ± 0.087 at month-three, and
0.757 ± 0.090 at month-four. Thus, an improvement of 0.027
QALYs (P = 0.008) between baseline and month-one occurred
(95% CI = 0.007–0.047). There were no other signiﬁcant
improvements, possibly due to patient dropouts. The sensitivity
analysis showed direct medical costs for buprenorphine treat-
ment ranged from $4206 to $6056 per person-year. By incorpo-
rating societal costs of untreated opiate addiction, a savings of
$36,901 to $38,752 per person-year was estimated. CONCLU-
SIONS: From a societal perspective, buprenorphine treatment
saves money and increases QALYs. For every 37 (95%CI =
21–143) patients treated there is a gain of one QALY. Wide-
spread adoption of proper ofﬁce-based buprenorphine treatment
is clearly indicated; undertreatment leads to exorbitant social
costs without QALY gains.
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OBJECTIVE: To estimate cost-effectiveness of Alprazolam
versus Clonazepam, Fluoxetine and Imipramine in anxiety dis-
orders in the Mexican Institute of Social Security (IMSS).
METHODS: A cost-effectiveness study was carried out with a
time horizon of one year, no discount rate was used. Utilization
of resources and effectiveness data were taken from an expert
panel of psychiatrists working at the IMSS and private sector.
Inclusion criteria for experts were: psychiatrists with more than
ﬁve years of clinical experience, that were certiﬁed by the
Mexican Council of Psychiatry and that had experience in using
the studied drugs in anxiety disorders. Use of resources included
hospitalisation, emergency services, visits, laboratory and diag-
nostic tests, as well as pocket expenses. Unit costs were taken
from Administrative and Financial departments of IMSS. Costs
were expressed in 2004 USD. Effectiveness measure was days
free of symptoms. Sensitivity analysis was univariate and prob-
abilistic. RESULTS: Annual treatment cost of anxiety disorders
with Alprazolam was $13,110, with Clonazepam $13,367, with
Fluoxetine $13,423 and with Imipramine $14,803. Effectiveness
results were 224 days without symptoms for Alprazolam, 232
